NLM Digital Collections

Search

Start Over Subjects Opiate Substitution Treatment ✖Remove constraint Subjects: Opiate Substitution Treatment Subjects Opioid-Related Disorders -- drug therapy ✖Remove constraint Subjects: Opioid-Related Disorders -- drug therapy

1. The role of community health centers in addressing the opioid epidemic

Author(s):
Zur, Julia, author
Tolbert, Jennifer, author
Sharac, Jessica, author
Markus, Anne, author
Publication:
San Francisco, CA : Henry J. Kaiser Family Foundation, July 2018
Subject(s):
Community Health Centers -- statistics & numerical data
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Drug Overdose -- epidemiology
Inservice Training
Medicaid
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Opiate Substitution Treatment
Practice Patterns, Physicians'
Prescription Drug Misuse -- statistics & numerical data
State Government
Humans
United States

2. Extended-release opioid agonists and antagonist medications for addiction treatment (MAT) in patients with opioid use disorder: effectiveness and value : final evidence report

Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 3, 2018
Subject(s):
Analgesics, Opioid -- therapeutic use
Narcotic Antagonists -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
Buprenorphine, Naloxone Drug Combination -- therapeutic use
Cost-Benefit Analysis
Methadone -- therapeutic use
Naltrexone -- therapeutic use
Treatment Outcome
Humans
United States

3. Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, October 2017
Subject(s):
Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Outcome Assessment (Health Care)
Community-Institutional Relations
Buprenorphine -- therapeutic use
Inservice Training
Insurance Coverage
Methadone -- therapeutic use
Naloxone -- therapeutic use
Naltrexone -- therapeutic use
Prescription Drug Diversion -- prevention & control
Humans
United States
United States. Department of Health and Human Services.

4. Why health plans should go to the "MAT" in the fight against opioid addiction

Author(s):
Elitzer, Julia, author
Tatar, Margaret, author
Publication:
[Oakland, Calif.] : California Health Care Foundation, September 2017
Subject(s):
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Opioid-Related Disorders -- prevention & control
Buprenorphine -- therapeutic use
Comparative Effectiveness Research
Cost Savings
Drug Overdose -- drug therapy
Drug Overdose -- prevention & control
Health Care Costs
Health Services Accessibility
Healthcare Disparities
Inappropriate Prescribing -- prevention & control
Insurance Coverage -- legislation & jurisprudence
Managed Care Programs
Medicaid
Mental Health Services -- legislation & jurisprudence
Methadone -- therapeutic use
Naloxone
Naltrexone -- therapeutic use
Neonatal Abstinence Syndrome -- drug therapy
Opioid-Related Disorders -- epidemiology
Patient Care Management
Prescription Drug Diversion
State Government
Humans
California
United States

5. Learning from COVID-19: how pandemic-era policies for methadone prescribing could improve opioid treatment

Author(s):
Suen, Leslie W., author
Nguyen, Oanh K., author
Knight, Kelly Ray, 1969- author
Publication:
[Oakland, California] : California Health Care Foundation, April 2022
Subject(s):
COVID-19
Methadone -- therapeutic use
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Drug Prescriptions
Health Policy
California

6. Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees

Publication:
Washington, DC : United States Government Accountability Office, January 2020
Subject(s):
Analgesics, Opioid -- supply & distribution
Analgesics, Opioid -- therapeutic use
Health Services Accessibility
Medicaid -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
Centers for Medicare & Medicaid Services (U.S.)

7. Geographic disparities affect access to buprenorphine services for opioid use disorder

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, January 2020
Subject(s):
Buprenorphine -- supply & distribution
Health Services Accessibility
Medically Underserved Area
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States
United States. Department of Health and Human Services
United States. Substance Abuse and Mental Health Services Administration

8. Lowering the barriers to medication treatment for people with opioid use disorder: evidence for a low-threshold approach

Author(s):
Aronowitz, Shoshana V., author
Behrends, Czarina Navos, author
Lowenstein, Margaret, author
Schackman, Bruce, author
Weiner, Janet, author
Publication:
Philadelphia, PA : Leonard Davis Institute of Health Economics, January 2022
Subject(s):
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Health Services Accessibility
United States

9. Increasing access to medications for opioid use disorder: policy strategies during and after COVID-19 pandemic

Author(s):
Au-Yeung, Caroline M., author
Blewett, Lynn A., author
Winkelman, Tyler N.A., author
Publication:
New York, NY : Milbank Memorial Fund, October 2021
Subject(s):
Health Services Accessibility
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Buprenorphine -- therapeutic use
COVID-19
Health Policy
Methadone -- therapeutic use
Naltrexone -- therapeutic use
United States

10. Opioid use disorder: developing depot buprenorphine products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, February 2019
Subject(s):
Buprenorphine -- therapeutic use
Drug Development
Opioid-Related Disorders -- drug therapy
Buprenorphine -- administration & dosage
Clinical Trials as Topic
Delayed-Action Preparations
Narcotic Antagonists
Opiate Substitution Treatment
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.